Medicinal Chemistry Journal of Medicinal Chemistry (ACS)

Coumarin-caged PD-L1 inhibitors stay silent in the dark and switch on with visible light

  • Two small-molecule PD-L1 inhibitors were masked with photolabile coumarin groups, at attachment points chosen from cocrystal binding modes.
  • In the dark the caged prodrugs were inactive; visible light released the parent inhibitors and restored T-cell function in PD-L1-dependent co-cultures.
  • The aim is local, on-demand checkpoint blockade that limits systemic immune toxicity, suited to superficial or light-accessible lesions.
Points Based on the abstract

Dimerizing biaryl PD-L1 binders are already greasy and borderline for cell potency, so a bulky coumarin cage only helps if it truly kills binding in the dark. I'd want a residual-activity control on the uncleaved prodrug and on the photolysis byproduct. Also, visible light barely penetrates tissue, so red-shifted cages would be my next ask.